Showing results (121-130 of 1,687) with videos related to
Sort By:
Pageof 169
The Oncologist|February 29, 2008
Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?Josep Tabernero, Per Pfeiffer, Andrés CervantesJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2015
Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patientsRodrigo Dienstmann, Ramon Salazar, Josep TaberneroAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Overcoming Resistance to Anti-EGFR Therapy in Colorectal CancerRodrigo Dienstmann, Ramon Salazar, Josep TaberneroCurrent Clinical Pharmacology|March 22, 2012
Application of monoclonal antibodies as cancer therapy in solid tumorsRodrigo Dienstmann, Ben Markman, Josep TaberneroAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 3, 2022
The Evolving Treatment Landscape in BRAF-V600E-Mutated Metastatic Colorectal CancerJosep Tabernero, Javier Ros, Elena ÉlezAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
Drug development in the era of personalized oncology: from population-based trials to enrichment and prescreening strategiesRodrigo Dienstmann, Jordi Rodon, Josep TaberneroCurrent Treatment Options in Oncology|September 17, 2015
First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405Elena Elez, Guillem Argilés, Josep TaberneroFuture Oncology (London, England)|November 13, 2025
BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line BRAF V600E-mutant metastatic colorectal cancerScott Kopetz, Josep Tabernero, Elena ÉlezCancer Journal (Sudbury, Mass.)|June 8, 2010
Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapyCésar Serrano, Ben Markman, Josep TaberneroOncotarget|February 15, 2011
Targeting the PI3K/Akt/mTOR pathway--beyond rapalogsBen Markman, Rodrigo Dienstmann, Josep TaberneroPageof 169